Lumida
/ANIK
⌘K
Anika Therapeutics Inc

Anika Therapeutics Inc

ANIK
$20.86USD↓-0.62%-0.13 today

MARKET CAP

279.2M

P/E (TTM)

38.2x

FWD P/E

72.2x

DAY RANGE

$21 – $21

52W RANGE

$8
$23

AI Summary

Stalk
Sell NowMedium

ANIK is in a Stage 3 distribution phase, granting bearish medium-term permission. Short-term price is rejecting around the 9/21 EMAs and 50-day SMA, reflecting diminishing demand and structure failure. The preferred execution is selling into rallies near these resistance zones, aligning with the dominant downtrend while respecting potential short-term oversold bounces.

  • ↑2026 EPS now projected at $1.05, reversing a prior $0.12 loss.
  • ↑Q2 revenue $32.6M (+16% YoY) with gross margin at 65% vs 51%.
  • ↓Balance sheet quality is suboptimal, with elevated leverage and liquidity risk.
Full analysis →

Buying

4

institutions

Selling

5

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

SELL1.45 M21.21 M+-145.22 K-8.3%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY559.85 K8.19 M+287.58 K+107.5%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL481.42 K7.04 M+-20.80 K-3.3%0.01%
MG

Man Group Plc

Q2 2026

BUY140.71 K2.06 M+16.42 K+14.2%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY54.22 K813.77 K+19.91 K+67.9%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

SELL22.52 K329.39 K+-6.71 K-22.3%0.00%
MM

Millennium Management LLC

Q2 2026

BUYNEW14.44 K211.21 K+14.44 K+0.0%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

SELL506.007.40 K+-566.00-52.4%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL0.000.00+-68.06 K-100.0%0.00%